{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:27:19Z","timestamp":1794425239238,"version":"4.9.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["SFB 1648\/1 2024 \\u2013 512741711"],"award-info":[{"award-number":["SFB 1648\/1 2024 \\u2013 512741711"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001866","name":"Fonds National de la Recherche Luxembourg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Centre for Infection Research","doi-asserted-by":"publisher","award":["TTU 01.702"],"award-info":[{"award-number":["TTU 01.702"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.coviro.2026.101537","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:19:24Z","timestamp":1776471564000},"page":"101537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting the virus\u2013host interface for the development of therapeutics against filoviruses"],"prefix":"10.1016","volume":"76","author":[{"given":"Juliette","family":"Dupr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly A","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Groseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Mu\u00f1oz-Fontela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5829-6305","authenticated-orcid":false,"given":"Thomas","family":"Hoenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2026.101537_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00985-y","article-title":"Filovirus vaccines as a response paradigm for emerging infectious diseases","volume":"9","author":"Marzi","year":"2024","journal-title":"NPJ Vaccin"},{"key":"10.1016\/j.coviro.2026.101537_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2023.01.002","article-title":"Structure of the Inmazeb cocktail and resistance to Ebola virus escape","volume":"31","author":"Rayaprolu","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2026.101537_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1083429","article-title":"Ebanga: the most recent FDA-approved drug for treating Ebola","volume":"14","author":"Taki","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coviro.2026.101537_bib4","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"The PREVAIL II Writing Group","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2026.101537_bib5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2026.101537_sbref6","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-59168-5","article-title":"Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus","volume":"16","author":"Prasad","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101537_sbref7","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-025-02766-y","article-title":"Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo","volume":"22","author":"Kikwango","year":"2025","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2026.101537_bib8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2026.101537_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.chom.2017.12.003","article-title":"The Marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding","volume":"23","author":"King","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2026.101537_bib10","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1073\/pnas.1914985117","article-title":"Development of an antibody cocktail for treatment of Sudan virus infection","volume":"117","author":"Herbert","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101537_bib11","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.chom.2020.03.025","article-title":"Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies","volume":"27","author":"Ilinykh","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2026.101537_bib12","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1016\/j.cell.2021.09.035","article-title":"Pan-Ebolavirus protective therapy by two multifunctional human antibodies","volume":"184","author":"Gilchuk","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2026.101537_sbref13","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01242-23","article-title":"Delayed treatment of cynomolgus macaques with a FVM04\/CA45 monoclonal antibody cocktail provides complete protection against lethal Sudan virus infection","volume":"98","author":"Chan","year":"2024","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2026.101537_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00035-6","article-title":"Solidarity against Ebola: an update","volume":"4","author":"Samarasekera","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.coviro.2026.101537_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56452-2","article-title":"Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP((1,2)) in a position elevated from the virion membrane","volume":"16","author":"Hastie","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101537_sbref16","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00296-25","article-title":"Monotherapy with antibody 1C3 partially protects Ebola virus-exposed macaques","volume":"99","author":"Worwa","year":"2025","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2026.101537_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","article-title":"Therapeutic strategies to target the Ebola virus life cycle","volume":"17","author":"Hoenen","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2026.101537_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.curtheres.2017.01.007","article-title":"Repurposed therapeutic agents targeting the Ebola virus: a systematic review","volume":"84","author":"Sweiti","year":"2017","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.coviro.2026.101537_bib19","doi-asserted-by":"crossref","first-page":"11786","DOI":"10.1021\/acs.jmedchem.5c00615","article-title":"From diarylsulfides to diarylamines: new Ebola virus entry inhibitors with improved metabolic stability","volume":"68","author":"Morales-Tenorio","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2026.101537_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130230","article-title":"Discovery of novel Ebola entry inhibitors with 1,2,3,4-tetrahydroisoquinoline-3-carboxamide based on (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold","volume":"123","author":"Lin","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2026.101537_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/md23010023","article-title":"Identification of filovirus entry inhibitors from marine fungus-derived indole alkaloids","volume":"23","author":"Wang","year":"2025","journal-title":"Mar Drugs"},{"key":"10.1016\/j.coviro.2026.101537_bib22","doi-asserted-by":"crossref","first-page":"16381","DOI":"10.1021\/acs.jmedchem.4c01267","article-title":"Discovery of thiophene derivatives as potent, orally bioavailable, and blood-brain barrier-permeable Ebola virus entry inhibitors","volume":"67","author":"Morales-Tenorio","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2026.101537_bib23","doi-asserted-by":"crossref","first-page":"13737","DOI":"10.1021\/acs.jmedchem.4c00527","article-title":"N-substituted pyrrole-based heterocycles as broad-spectrum filoviral entry inhibitors","volume":"67","author":"Durante","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2026.101537_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-44504-4","article-title":"Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1","volume":"15","author":"Khan","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101537_bib25","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1021\/acs.jmedchem.2c01785","article-title":"N'-phenylacetohydrazide derivatives as potent Ebola virus entry inhibitors with an improved pharmacokinetic profile","volume":"66","author":"Garcia-Rubia","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2026.101537_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009312","article-title":"Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry","volume":"17","author":"Schafer","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2026.101537_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105399","article-title":"Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses","volume":"206","author":"Wang","year":"2022","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2026.101537_bib28","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41564-019-0453-2","article-title":"Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry","volume":"4","author":"Perez-Zsolt","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2026.101537_bib29","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12177","article-title":"Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection","volume":"4","author":"Lu","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.coviro.2026.101537_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012444","article-title":"Genome-wide CRISPR\/Cas9 screen identifies SLC39A9 and PIK3C3 as crucial entry factors for Ebola virus infection","volume":"20","author":"Gong","year":"2024","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2026.101537_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116537","article-title":"Evaluation of potency and metabolic stability of diphyllin-derived Vacuolar-ATPase inhibitors","volume":"275","author":"Sanford","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.coviro.2026.101537_bib32","doi-asserted-by":"crossref","first-page":"e00168","DOI":"10.1128\/CMR.00168-19","article-title":"Host-directed antiviral therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coviro.2026.101537_bib33","doi-asserted-by":"crossref","first-page":"11701","DOI":"10.1021\/acs.jmedchem.3c00750","article-title":"Discovery of GS-5245 (Obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys","volume":"66","author":"Mackman","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2026.101537_sbref34","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk6176","article-title":"Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus","volume":"383","author":"Cross","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.coviro.2026.101537_bib35","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41591-025-03496-y","article-title":"Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates","volume":"31","author":"Cross","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2026.101537_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adw0659","article-title":"The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection","volume":"11","author":"Woolsey","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.coviro.2026.101537_bib37","article-title":"Structural insights into the RNA-dependent RNA polymerase complexes from highly pathogenic Marburg and Ebola viruses","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101537_bib38","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41401-023-01055-0","article-title":"Inhibiting the transcription and replication of Ebola viruses by disrupting the nucleoprotein and VP30 protein interaction with small molecules","volume":"44","author":"Ma","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.coviro.2026.101537_bib39","article-title":"The synergy between nucleotide biosynthesis inhibitors and antiviral nucleosides: new opportunities against viral infections?","volume":"356","author":"de Mariz","year":"2023","journal-title":"Arch Pharm"},{"key":"10.1016\/j.coviro.2026.101537_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116069","article-title":"Broad-spectrum antiviral strategy: host-targeting antivirals against emerging and re-emerging viruses","volume":"265","author":"He","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.coviro.2026.101537_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-018-0570-1","article-title":"A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle","volume":"10","author":"Martin","year":"2018","journal-title":"Genome Med"},{"key":"10.1016\/j.coviro.2026.101537_bib42","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/cells9051126","article-title":"The cellular protein CAD is recruited into Ebola virus inclusion bodies by the nucleoprotein NP to facilitate genome replication and transcription","volume":"9","author":"Brandt","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.coviro.2026.101537_bib43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2018.08.012","article-title":"Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses","volume":"158","author":"Luthra","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2026.101537_bib44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","volume":"11","author":"Xiong","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.coviro.2026.101537_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105161","article-title":"Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro","volume":"194","author":"Gong","year":"2021","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2026.101537_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198246","article-title":"The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines","volume":"292","author":"Luban","year":"2021","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2026.101537_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106099","article-title":"DHODH inhibitors: what will it take to get them into the clinic as antivirals?","volume":"236","author":"Luganini","year":"2025","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2026.101537_sbref48","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1038\/s41564-025-02034-3","article-title":"Single-cell image-based screens identify host regulators of Ebola virus infection dynamics","volume":"10","author":"Carlson","year":"2025","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2026.101537_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0334160","article-title":"Exploration of African natural products as VP35 inhibitors to combat Marburg virus infection: molecular docking, molecular dynamics, and quantum mechanical computations","volume":"20","author":"Abdelrahman","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2026.101537_bib50","doi-asserted-by":"crossref","DOI":"10.1007\/s40203-025-00323-7","article-title":"In-silico repurposing of antiviral compounds against Marburg virus: a computational drug discovery approach","volume":"13","author":"Singh","year":"2025","journal-title":"In Silico Pharmacol"},{"key":"10.1016\/j.coviro.2026.101537_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106167","article-title":"Mechanisms of action of repurposed Ebola virus antivirals \u2013 the roles of phospholipidosis and cholesterol homeostasis","volume":"238","author":"Kelly","year":"2025","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2026.101537_bib52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1021\/acs.jmedchem.4c01646","article-title":"Guardians at the gate: optimization of small molecule entry inhibitors of Ebola and Marburg viruses","volume":"68","author":"Argade","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2026.101537_sbref53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1533037","article-title":"SuFEx-enabled high-throughput medicinal chemistry for developing potent tamoxifen analogs as Ebola virus entry inhibitors","volume":"16","author":"Dada","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2026.101537_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104569","article-title":"High-throughput screening for negative-stranded hemorrhagic fever viruses using reverse genetics","volume":"170","author":"Wendt","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2026.101537_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22132-0","article-title":"Combination therapy protects macaques against advanced Marburg virus disease","volume":"12","author":"Cross","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101537_sbref56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159090","article-title":"Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease","volume":"7","author":"Cross","year":"2022","journal-title":"JCI Insight"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625726000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625726000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:19:34Z","timestamp":1794424774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625726000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"alternative-id":["S1879625726000295"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101537","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the virus\u2013host interface for the development of therapeutics against filoviruses","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101537"}}